Adoption of new agents and changes in treatment patterns for Hepatitis C

2010-2014

Xiaoxi Yao, Lindsey R. Sangaralingham, Joseph S. Ross, Nilay D Shah, Jayant A. Talwalkar

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Objectives: A number of new hepatitis C virus (HCV) medications have become available in the United States, but little is known about how these treatments have been adopted into practice and their financial burden on patients. The aim of this study was to examine whether the introduction of new HCV medications was associated with changes in treatment rates and out-of-pocket (OOP) costs. Study Design: Retrospective analysis of administrative claims data from Optum Labs Data Warehouse. Methods: We performed a retrospective analysis using a large, US commercial insurance database to identify 56,116 adults with chronic HCV between January 1, 2010, and December 31, 2014. Logistic regression was performed to calculate patients' predicted probability of being treated before and after the new medications became available. Results: A total of 5436 (9.7%) of patients with HCV received treatment during an average of 1.8 years of follow-up. In the last quarter of 2014, 0.1% of patients with HCV received interferon/ ribavirin as the primary treatment; no one received boceprevir or telaprevir, 1.1% received sofosbuvir combined with simeprevir, 1.4% received sofosbuvir or simeprevir alone, and 2.0% received ledipasvir/sofosbuvir. The introduction of new medications was significantly associated with an increased treatment rate, from 5.4% to 6.8% (P

Original languageEnglish (US)
Pages (from-to)e224-e232
JournalAmerican Journal of Managed Care
Volume22
Issue number6
StatePublished - Jun 1 2016

Fingerprint

Hepatitis C
Hepacivirus
Insurance Claim Review
Therapeutics
Ribavirin
Chronic Hepatitis C
Health Expenditures
Insurance
Interferons
Retrospective Studies
Logistic Models
Databases
Sofosbuvir
Simeprevir

ASJC Scopus subject areas

  • Health Policy

Cite this

Adoption of new agents and changes in treatment patterns for Hepatitis C : 2010-2014. / Yao, Xiaoxi; Sangaralingham, Lindsey R.; Ross, Joseph S.; Shah, Nilay D; Talwalkar, Jayant A.

In: American Journal of Managed Care, Vol. 22, No. 6, 01.06.2016, p. e224-e232.

Research output: Contribution to journalArticle

Yao, X, Sangaralingham, LR, Ross, JS, Shah, ND & Talwalkar, JA 2016, 'Adoption of new agents and changes in treatment patterns for Hepatitis C: 2010-2014', American Journal of Managed Care, vol. 22, no. 6, pp. e224-e232.
Yao, Xiaoxi ; Sangaralingham, Lindsey R. ; Ross, Joseph S. ; Shah, Nilay D ; Talwalkar, Jayant A. / Adoption of new agents and changes in treatment patterns for Hepatitis C : 2010-2014. In: American Journal of Managed Care. 2016 ; Vol. 22, No. 6. pp. e224-e232.
@article{175b80ad07634c95bfe63a829432b52c,
title = "Adoption of new agents and changes in treatment patterns for Hepatitis C: 2010-2014",
abstract = "Objectives: A number of new hepatitis C virus (HCV) medications have become available in the United States, but little is known about how these treatments have been adopted into practice and their financial burden on patients. The aim of this study was to examine whether the introduction of new HCV medications was associated with changes in treatment rates and out-of-pocket (OOP) costs. Study Design: Retrospective analysis of administrative claims data from Optum Labs Data Warehouse. Methods: We performed a retrospective analysis using a large, US commercial insurance database to identify 56,116 adults with chronic HCV between January 1, 2010, and December 31, 2014. Logistic regression was performed to calculate patients' predicted probability of being treated before and after the new medications became available. Results: A total of 5436 (9.7{\%}) of patients with HCV received treatment during an average of 1.8 years of follow-up. In the last quarter of 2014, 0.1{\%} of patients with HCV received interferon/ ribavirin as the primary treatment; no one received boceprevir or telaprevir, 1.1{\%} received sofosbuvir combined with simeprevir, 1.4{\%} received sofosbuvir or simeprevir alone, and 2.0{\%} received ledipasvir/sofosbuvir. The introduction of new medications was significantly associated with an increased treatment rate, from 5.4{\%} to 6.8{\%} (P",
author = "Xiaoxi Yao and Sangaralingham, {Lindsey R.} and Ross, {Joseph S.} and Shah, {Nilay D} and Talwalkar, {Jayant A.}",
year = "2016",
month = "6",
day = "1",
language = "English (US)",
volume = "22",
pages = "e224--e232",
journal = "American Journal of Managed Care",
issn = "1088-0224",
publisher = "Ascend Media",
number = "6",

}

TY - JOUR

T1 - Adoption of new agents and changes in treatment patterns for Hepatitis C

T2 - 2010-2014

AU - Yao, Xiaoxi

AU - Sangaralingham, Lindsey R.

AU - Ross, Joseph S.

AU - Shah, Nilay D

AU - Talwalkar, Jayant A.

PY - 2016/6/1

Y1 - 2016/6/1

N2 - Objectives: A number of new hepatitis C virus (HCV) medications have become available in the United States, but little is known about how these treatments have been adopted into practice and their financial burden on patients. The aim of this study was to examine whether the introduction of new HCV medications was associated with changes in treatment rates and out-of-pocket (OOP) costs. Study Design: Retrospective analysis of administrative claims data from Optum Labs Data Warehouse. Methods: We performed a retrospective analysis using a large, US commercial insurance database to identify 56,116 adults with chronic HCV between January 1, 2010, and December 31, 2014. Logistic regression was performed to calculate patients' predicted probability of being treated before and after the new medications became available. Results: A total of 5436 (9.7%) of patients with HCV received treatment during an average of 1.8 years of follow-up. In the last quarter of 2014, 0.1% of patients with HCV received interferon/ ribavirin as the primary treatment; no one received boceprevir or telaprevir, 1.1% received sofosbuvir combined with simeprevir, 1.4% received sofosbuvir or simeprevir alone, and 2.0% received ledipasvir/sofosbuvir. The introduction of new medications was significantly associated with an increased treatment rate, from 5.4% to 6.8% (P

AB - Objectives: A number of new hepatitis C virus (HCV) medications have become available in the United States, but little is known about how these treatments have been adopted into practice and their financial burden on patients. The aim of this study was to examine whether the introduction of new HCV medications was associated with changes in treatment rates and out-of-pocket (OOP) costs. Study Design: Retrospective analysis of administrative claims data from Optum Labs Data Warehouse. Methods: We performed a retrospective analysis using a large, US commercial insurance database to identify 56,116 adults with chronic HCV between January 1, 2010, and December 31, 2014. Logistic regression was performed to calculate patients' predicted probability of being treated before and after the new medications became available. Results: A total of 5436 (9.7%) of patients with HCV received treatment during an average of 1.8 years of follow-up. In the last quarter of 2014, 0.1% of patients with HCV received interferon/ ribavirin as the primary treatment; no one received boceprevir or telaprevir, 1.1% received sofosbuvir combined with simeprevir, 1.4% received sofosbuvir or simeprevir alone, and 2.0% received ledipasvir/sofosbuvir. The introduction of new medications was significantly associated with an increased treatment rate, from 5.4% to 6.8% (P

UR - http://www.scopus.com/inward/record.url?scp=84975270363&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84975270363&partnerID=8YFLogxK

M3 - Article

VL - 22

SP - e224-e232

JO - American Journal of Managed Care

JF - American Journal of Managed Care

SN - 1088-0224

IS - 6

ER -